CAMBRIDGE, Mass. April 5, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that company management will participate in 1×1...
CAMBRIDGE, Mass. March 10, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that Apnimed will participate in the 32nd Annual...
– Positive Data on Investigational Oral Pharmacologic Treatment AD109 Showed Statistically Significant and Clinically Meaningful Benefits for Patients with Obstructive Sleep Apnea CAMBRIDGE, Mass. March 9, 2022 – Apnimed, a clinical-stage pharmaceutical company...
CAMBRIDGE, Mass. February 7, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that company management will participate in...
CAMBRIDGE, Mass. January 6, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced it will present at the JP Morgan 40th Annual...
